A Phase 1 interventional study of quitSTART Mobile Application and Chatbot Feature in quitSTART Mobile Application in Nicotine Vaping and Nicotine Use Disorder, sponsored by Washington University School of Medicine. Terminated at 1 site in United States. Open to participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment
Due to low recruitment
Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. With limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to associated health risks. Teens and young adults may be reluctant to disclose their use of vaping products to parents or health providers and instead turn to social media to share and seek out information regarding vaping risks and cessation supports. Thus, our current proposal outlines the use of social media to identify teens and young adults socially networking about vaping, the use of an online chatbot screen to evaluate individual cessation support needs, and the use of a digital intervention system to support vaping cessation. The mobile intervention used in this study is based on a widely-used evidence-based mobile intervention for combustible smoking (i.e., quitSTART) and has been adapted for vaping and young adults to include an in-app chatbot to guide users to tailored content and to motivate and encourage their cessation efforts. We aim to integrate our social media recruitment and online screening approach to connect individuals with this mobile app intervention, and will conduct a randomized controlled trial to evaluate user engagement with and preliminary efficacy of the digital intervention on reducing vaping behaviors among teens and young adults.
402 studies on the registry are indexed under Vaping; 95 are open to participants now.
This study's enrollment of 26 is below the median of 79 across 322 interventional studies indexed under Vaping.
Browse Vaping studies →Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Nationwide resource referral and intervention waitlist
quitSTART Mobile Application Adapted for Vaping Cessation Among Young Adults
Device: quitSTART Mobile Application
quitSTART Mobile Application Adapted for Vaping Cessation Among Young Adults Including Embedded Chatbot Feature
Device: quitSTART Mobile Application · Behavioral: Chatbot Feature in quitSTART Mobile Application
Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
Vaping cessation
Vaping cessation as assessed by 7 day self-reported vaping abstinence at follow-up. Timeline follow back procedures will be used to establish abstinence or if participants lapsed (their first instance of vaping post quit) or relapsed (vaped on 7 consecutive days) at each follow up time point.
Time frame: Baseline, 6 weeks, 3 months
Nicotine dependence
Nicotine dependence will be assessed using the 4-item Patient-Reported Outcomes Measurement Information System (PROMIS).
Time frame: Baseline, 6 weeks, 3 months
Risk perception related to vaping
Perceived risks of vaping, both general and conditional, will be assessed with two items adapted from Wackowski et al., 2020. "How harmful, if at all, do you think vaping/using an e-cigarette is to a user's health?" (general) and "Imagine you vaped/used e-cigarettes daily for the next 10 years and used no other tobacco product. How harmful do you think this vaping would be to your health?" (conditional), both using a five-point response scale (not at all-extremely harmful).
Time frame: Baseline, 6 weeks, 3 months
Intervention engagement
Data automatically captured within the chatbot, and app platform will be used to calculate a composite measure of engagement for those randomized to each of these intervention components and will be examined as a predictor of outcomes. We will use a modified version of an app Engagement Index (EI).
Time frame: Baseline, 6 weeks, 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jun 2026, 12 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → Jun 2026 and completion Mar 2027 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Due to low recruitment
Due to low recruitment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →